Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -120% Improvement Relative Risk ICU admission 87% Vitamin D for COVID-19  Cereda et al.  Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Prospective study of 129 patients in Italy Higher mortality with higher vitamin D levels (p=0.038) c19early.org Cereda et al., Clinical Nutrition, Nov 2020 Favors vitamin D Favors control

Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital

Cereda et al., Clinical Nutrition (Edinburgh, Scotland), doi:10.1016/j.clnu.2020.10.055
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 119 studies, recognized in 7 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19early.org
Prospective cohort study of 129 adult hospitalized COVID-19 patients finding patients with vitamin D levels >20ng/mL had increased mortality after adjustment. This study does not account for the risk of having a serious enough case to be hospitalized, and adjustments for factors correlated with vitamin D levels could obscure a potential association with vitamin D levels.
This is the 25th of 192 COVID-19 sufficiency studies for vitamin D, which collectively show higher levels reduce risk with p<0.0000000001 (1 in 611 vigintillion).
risk of death, 120.0% higher, RR 2.20, p = 0.04, high D levels 10 of 30 (33.3%), low D levels 24 of 99 (24.2%), inverted to make RR<1 favor high D levels, odds ratio converted to relative risk, >20ng/mL.
risk of ICU admission, 86.7% lower, RR 0.13, p = 0.59, high D levels 0 of 30 (0.0%), low D levels 5 of 99 (5.1%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cereda et al., 1 Nov 2020, prospective, Italy, peer-reviewed, 13 authors.
This PaperVitamin DAll
Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital
Emanuele Cereda, Laura Bogliolo, Catherine Klersy, Federica Lobascio, Sara Masi, Silvia Crotti, Ludovico De Stefano, Raffaele Bruno, Angelo Guido Corsico, Antonio Di Sabatino, Stefano Perlini, Carlomaurizio Montecucco, Riccardo Caccialanza, San Matteo, Pavia Collaborative Group
doi:10.1016/j.clnu.2020.10.055
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Author contributions Caccialanza, Cereda and Bogliolo had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of data analysis. Caccialanza is chief investigators and act as guarantors for this work. Concept and design: Caccialanza, Cereda, Bogliolo, Klersy. Acquisition, analysis, or interpretation of data: Caccialanza, Cereda, Bogliolo, Klersy, Lobascio, Masi, Crotti, De Stefano, Mariani, Ludovisi, Muggia, Croce, Barteselli, Mambella, Di Terlizzi, Belliato. Drafting of the manuscript: Caccialanza, Cereda, Bogliolo, Klersy. Critical revision of the manuscript for important intellectual content: Montecucco, Di Sabatino, Corsico, Perlini, Bruno. Statistical analysis: Klersy. Administrative, technical, or material support: Ferrari. Supervision: Caccialanza. Other -Research facilitator responsible for data collection from participants: Mariani, Ludovisi, Muggia, Croce, Barteselli, Mambella, Di Terlizzi. Other -Trial management: Cereda, Bogliolo, Masi, Crotti, De Stefano, Lobascio. Additional contributions We are grateful to all the employees of the Fondazione IRCCS Policlinico San Matteo for their courageous efforts in struggling against the clinical and social COVID-19 emergency. Conflict of interest None of the authors have conflicts of interest to disclose.
References
Castillo, Costa, Barrios, Díaz, Opez Miranda et al., Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: a pilot randomized clinical study, J Steroid Biochem Mol Biol
Daneshkhah, Agrawal, Eshein, Subramanian, Roy et al., Evidence for possible association of vitamin D status with cytokine storm and unregulated inflammation in COVID-19 patients, Aging Clin Exp Res
Duncan, Talwar, Mcmillan, Stefanowicz, Reilly, Quantitative data on the magnitude of the systemic inflammatory response and its effect on micronutrient status based on plasma measurements, Am J Clin Nutr
Mardani, Alamdary, Nasab, Gholami, Ahmadi et al., Association of vitamin D with the modulation of the disease severity in COVID-19, Virus Res
Merad, Martin, Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages, Nat Rev Immunol
Montazeri, Nasiri, Shirvani, Holick, Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection, PloS One
Panagiotou, Tee, Ihsan, Athar, Marchitelli et al., Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity, Clin Endocrinol, doi:10.1111/cen.14276
Radujkovic, Hippchen, Tiwari-Heckler, Dreher, Boxberger, Vitamin D deficiency and outcome of COVID-19 patients, Nutrients
Reijven, Soeters, Vitamin D: a magic bullet or a myth?, Clin Nutr
Rhodes, Subramanian, Laird, Griffin, Kenny, Perspective: vitamin D deficiency and COVID-19 severity -plausibly linked by latitude, ethnicity, impacts on cytokines, ACE2 and thrombosis, J Intern Med, doi:10.1111/joim.13149
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit